19 short time to download the drug in the treatment of raw materials such as 4 days and 11 days, was synthesized by scientists and was manufactured in Turkey Turkey idealdat the author

0
5



© Reuters. Covidien – 11 days 4 19 treatment of drug raw materials to download as soon as the day was synthesized by Turkish scientists and was manufactured in Turkey

Covidien – 11 days 4 19 treatment of drug raw materials to download as soon as the day was synthesized by Turkish scientists and was manufactured in Turkey.

The statement is as follows:

Covidien – 19 used in the treatment and the recovery period of the disease in a clinical study conducted in China 11 days to 4 days hath seen the raw material for synthesizing drugs Favipirav named Turkey’s domestic and national drug was manufactured. Dr. from Üsküdar University. Lecturer. A team of 32 people, including its member Salih Tuncay as a team leader, is now working on a new drug.

Covidien – 11 days 4 19 treatment of drug raw materials to download as soon as the day was synthesized by Turkish scientists and was manufactured in Turkey. The team producing the drug called Favicovir, Üsküdar University Food Technology Program Head. Lecturer. His member Salih Tuncay was also present.

Shorten the treatment time

Stating that they started their synthesis studies on May 1, 2020 within the scope of TÜBİTAK 1004 project with the cooperation of Medipol University-Atabay Pharmaceutical Industry, Tuncay said, “A drug used in the treatment of Kovid-19, which has been shown to reduce the healing process of the disease from 11 days to 4 days, within TÜBİTAK. a first state in Turkey, aimed to synthesize the context of university-industry cooperation. this, again both in our country in the goal aimed come forward in healing the diseases in clinical treatment in foreign countries to synthesize different antiviral drugs as local and national. in addition, the different active derivatives of these drugs also The synthesis of favipiravir was produced on a laboratory scale for this purpose. The industrial scale studies were completed, produced and the license of the drug was obtained on July 10, 2020 as a result of the bio-equivalence studies of the drug were completed immediately. ”

Completed in 40 days with a team of 32

Stating that he is carrying out intensive studies on the total synthesis of active molecules that can be drugs for different diseases, Tuncay said, “I was involved in the project as a team leader and researcher for the synthesis of three drugs determined just before the epidemic. 12 people from the academy led by Assoc. Prof. Dr. Mustafa Güzel and Zeynep Atabay Taşkent A team of 32 people, with the participation of 20 people from the industry, worked in the production of this drug.After the post-doctorate studies from different universities, scientists were included in the project as researchers or scholarship.We produced the raw material of favipiravir drug in 40 days with the devoted work of the team. We have made it available for the treatment of patients under the name ‘Favicovir’. ”

Another new drug is coming

Stating that the synthesis of the hydroxychloroquine drug as well as the Favipiravir drug has been completed on a laboratory scale, Tuncay continued as follows:

“We continue to work rapidly to produce on a large scale and we have come to an end in optimization studies for the industrial scale. The studies that will be carried out will strengthen our country in the fight against the pandemic, as well as contributing to our health sector to provide better quality service to our people. It will provide. ”

-iDeal News Center-

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

LEAVE A REPLY

Please enter your comment!
Please enter your name here